Prime Medicine (NASDAQ:PRME) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Trading volume rose 10% above average to about 3.61 million shares; PRME last traded at $3.91.
• Prime Medicine priced an offering of 35.7 million shares at $3.50 each, expected to raise about $125 million. The proceeds support therapy development, while the below-market price and share issuance may dilute existing holders.
• Analysts give the stock a Moderate Buy consensus with an average $7.86 price target, though ratings include one Sell alongside eight Buy or Strong Buy ratings.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) saw strong trading volume on Wednesday. Approximately 3,609,477 shares traded hands during trading, an increase of 10% from the average daily volume of 3,296,173 shares. The stock last traded at $3.9110 and had previously closed at $3.90.

Trending Headlines about Prime Medicine

Here are a few of the latest headlines about PRME:

• Positive Sentiment: The sale is expected to raise approximately $125 million in gross proceeds for Prime Medicine, providing additional capital to develop its investigational therapies. The offering is expected to close around November 12, subject to customary conditions. Prime Medicine Announces Pricing of Public Offering of Common Stock
• Negative Sentiment: Prime Medicine is issuing 35.7 million new shares at $3.50 per share, with underwriters able to buy up to 5.36 million additional shares. The added shares dilute existing investors, and the offering price is below the recent trading level, potentially creating near-term downward pressure on PRME. Prime Medicine Prices Offering

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Prime Medicine in a research report on Monday, August 31st. Citigroup reiterated a "market outperform" rating on shares of Prime Medicine in a report on Friday, September 25th. Wall Street Zen raised Prime Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, October 31st. Chardan Capital restated a "buy" rating and set a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of Prime Medicine in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Prime Medicine currently has an average rating of "Moderate Buy" and an average price target of $7.86.

Prime Medicine Price Performance

The company has a market cap of $773.59 million, a PE ratio of -4.01 and a beta of 2.14. The business has a 50 day moving average of $3.67 and a 200 day moving average of $3.51.

Institutional Investors Weigh In On Prime Medicine

Several institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System boosted its stake in shares of Prime Medicine by 15.5% during the 2nd quarter. Arizona State Retirement System now owns 28,646 shares of the company's stock valued at $106,000 after purchasing an additional 3,855 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Prime Medicine by 15.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 33,094 shares of the company's stock worth $102,000 after buying an additional 4,349 shares in the last quarter. Royal Bank of Canada raised its stake in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company's stock worth $32,000 after buying an additional 4,365 shares in the last quarter. Swiss National Bank raised its stake in Prime Medicine by 5.0% in the first quarter. Swiss National Bank now owns 178,600 shares of the company's stock worth $622,000 after buying an additional 8,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Prime Medicine in the third quarter worth about $28,000. 70.37% of the stock is owned by hedge funds and other institutional investors.

About Prime Medicine

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.